474082-35-4

Usage

Uses

Used in Pharmaceutical Industry:
Amino-PEG9-Amine is used as a molecular linker for the conjugation of drugs and targeting moieties to enhance the pharmacokinetic properties and targeting efficiency of therapeutic agents. The amine groups facilitate covalent bonding with drug molecules, improving their solubility, stability, and bioavailability, while the PEG spacer reduces immunogenicity and promotes prolonged circulation in the body.
Used in Bioconjugation and Labeling:
In the field of biochemistry and molecular biology, Amino-PEG9-Amine serves as a versatile linker for the creation of bioconjugates and the labeling of biomolecules. The reactive amine groups enable the formation of stable amide bonds with carboxylic acid-modified biomolecules, such as proteins, peptides, and nucleic acids, allowing for the development of novel biosensors, imaging agents, and drug delivery systems.
Used in Materials Science:
Amino-PEG9-Amine is utilized as a key component in the synthesis of stimuli-responsive hydrogels, micelles, and other nanostructures for various applications, including drug delivery, tissue engineering, and diagnostics. The hydrophilic PEG spacer and reactive amine groups contribute to the formation of stable, well-defined structures with tunable properties, such as swelling behavior, degradation rate, and release kinetics.
Used in Diagnostics:
In the diagnostics industry, Amino-PEG9-Amine is employed as a building block for the development of contrast agents and imaging probes. The PEG spacer improves the solubility and circulation time of these agents in the body, while the amine groups allow for the attachment of targeting ligands and imaging labels, enhancing the specificity and sensitivity of diagnostic assays.
Overall, Amino-PEG9-Amine is a versatile and valuable molecule with a wide range of applications across various industries, including pharmaceuticals, biochemistry, materials science, and diagnostics, due to its unique structure and functional groups.

Upstream product

• 77544-60-6 p-toluenesulfonic acid 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl ester 
• 86770-67-4 2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethanol 
• 134179-43-4 11-azide-1-{(methylsulfonyl)oxy}-3,6,9-trioxaundecane 
• 42749-28-0 toluene-4-sulfonic acid 2-[2-(2-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethyl ester 
• 86770-69-6 17-azido-3,6,9,12,15-pentaoxaheptadecan-1-ol 
• 112-60-7 Tetraethylene glycol 
• 42749-27-9 hexa(ethyleneglycol) ditosylate 
• 5579-66-8 decaethylene glycol 
• 2615-15-8 pentaethylene glycol 
• 125274-14-8 2-{2-[2-(2-{2-[2-(2-{2-[2-(2-trityloxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethanol 
• 474082-33-2 decaethylene glycol dimesylate 

Downstream Products

• 890091-43-7 tert-butyl 2-(2-(2-(2-(2-(2-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethylcarbamate 

Relevant academic research and scientific papers

Bivalent HIV-1 fusion inhibitors based on peptidomimetics

Membrane fusion is a valid target for inhibition of HIV-1 replication. A 34-mer fragment peptide (C34), which is contained in the HIV-1 envelope protein gp41, has significant anti-HIV activity. Previously, a dimeric derivative of C34 linked by a disulfide bridge at its C-terminus was found to have more potent anti-HIV activity than the C34 peptide monomer. To date, several peptidomimetic small inhibitors have been reported, but most have lower potency than peptide derivatives related to C34. In the present study we applied this dimerization concept to these peptidomimetic small inhibitors and designed several bivalent peptidomimetic HIV-1 fusion inhibitors. The importance of the length of linkers crosslinking two peptidomimetic compounds was demonstrated and several potent bivalent inhibitors containing tethered peptidomimetics were produced.

BIFUNCTIONAL ANTIFUNGAL AGENTS AND METHODS OF TREATING FUNGAL INFECTION

The present invention is directed to bifunctional compounds which are useful in the treatment of fungal infections. The present compounds contains at least one fungal binding moiety (FBM) which is linked to at least one antibody binding moiety (ΑB/s

Neutralization of Pathogenic Fungi with Small-Molecule Immunotherapeutics

Systemic fungal infections represent an important public health concern, and new antifungal agents are highly desirable. Herein, we describe the design, synthesis, and biological evaluation of a novel class of antifungal compounds called antibody-recruiting molecules targeting fungi (ARM-Fs). Our approach relies on the use of non-peptidic small molecules, which selectively bind fungal cells and recruit endogenous antibodies to their surfaces, resulting in immune-mediated clearance. Using the opportunistic fungal pathogen Candida albicans as a model, we identified a highly specific bifunctional molecule able to mediate the engulfment and phagocytosis of C. albicans cells by human immune cells in biologically relevant functional assays. This work represents a novel therapeutic approach to treating fungal illness with significant potential to complement and/or combine with existing treatment strategies.

An ion conductor that recognizes osmotically-stressed phospholipid bilayers

A synthetic ion conductor (1), derived from cholic acid and spermine, has been found capable of recognizing osmotic stress in liposomes made from 1,2-dipalmitoleoyl-sn-glycero-3-phosphocholine [(C16:1)PC]. Thus, when large unilamellar vesicles of (C16:1)PC are placed under hypotonic conditions, the Na+/Li+ transport activity of 1 increases by as much as 1 order of magnitude, relative to isotonic conditions Copyright